Application segmentation of the Riociguat market is dominated by two therapeutic indications: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). In PAH, Riociguat functions as a soluble guanylate cyclase stimulator, addressing endothelial dysfunction and providing hemodynamic improvement; this indication accounts for roughly 58 % of total sales due to its broader patient base and earlier adoption in treatment algorithms. CTEPH, representing post‑operative residual disease, contributes the remaining 42 % of revenue, reflecting its niche yet high‑value positioning in specialized pulmonary hypertension centers. The relative weight of each application directly influences manufacturing volume, pricing strategies, and reimbursement negotiations, making the Riociguat segmentation by indication a primary driver of market size. Geographic variations further modulate these shares, with North America favoring PAH and Europe showing a slightly higher proportion of CTEPH prescriptions, but the overall global split remains anchored by the clinical prevalence of the two conditions. Consequently, investment in clinical‑trial programs for PAH continues to dominate R&D budgets, while CTEPH‑focused initiatives receive targeted funding to sustain market momentum.
